JP5005879B2 - Anti-stress and relaxing composition - Google Patents
Anti-stress and relaxing composition Download PDFInfo
- Publication number
- JP5005879B2 JP5005879B2 JP2004041255A JP2004041255A JP5005879B2 JP 5005879 B2 JP5005879 B2 JP 5005879B2 JP 2004041255 A JP2004041255 A JP 2004041255A JP 2004041255 A JP2004041255 A JP 2004041255A JP 5005879 B2 JP5005879 B2 JP 5005879B2
- Authority
- JP
- Japan
- Prior art keywords
- theanine
- stress
- anxiety
- group
- wort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title description 56
- 230000002180 anti-stress Effects 0.000 title description 48
- 230000001390 anti-relaxing effect Effects 0.000 title description 9
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 306
- 229940026510 theanine Drugs 0.000 claims description 149
- 208000019901 Anxiety disease Diseases 0.000 claims description 79
- 230000036506 anxiety Effects 0.000 claims description 79
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 45
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 35
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 33
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 31
- 244000141009 Hypericum perforatum Species 0.000 claims description 30
- 235000011925 Passiflora alata Nutrition 0.000 claims description 24
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 24
- 235000011922 Passiflora incarnata Nutrition 0.000 claims description 24
- 235000013750 Passiflora mixta Nutrition 0.000 claims description 24
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims description 24
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 23
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 23
- 240000002690 Passiflora mixta Species 0.000 claims description 23
- 241000906543 Actaea racemosa Species 0.000 claims description 8
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 8
- 235000005301 cimicifuga racemosa Nutrition 0.000 claims description 8
- 235000020710 ginseng extract Nutrition 0.000 claims description 8
- 230000002040 relaxant effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 description 24
- 235000013832 Valeriana officinalis Nutrition 0.000 description 23
- 244000126014 Valeriana officinalis Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 235000016788 valerian Nutrition 0.000 description 23
- 240000003538 Chamaemelum nobile Species 0.000 description 22
- 239000002994 raw material Substances 0.000 description 22
- 235000010654 Melissa officinalis Nutrition 0.000 description 20
- 244000062730 Melissa officinalis Species 0.000 description 20
- 244000269722 Thea sinensis Species 0.000 description 20
- 235000008216 herbs Nutrition 0.000 description 19
- 239000003205 fragrance Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 235000005979 Citrus limon Nutrition 0.000 description 16
- 244000131522 Citrus pyriformis Species 0.000 description 16
- 230000035882 stress Effects 0.000 description 16
- 229930006000 Sucrose Natural products 0.000 description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 15
- 235000019634 flavors Nutrition 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000005720 sucrose Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 13
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 13
- 235000021014 blueberries Nutrition 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
- 235000013339 cereals Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- -1 patches Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 11
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 240000000851 Vaccinium corymbosum Species 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 244000025221 Humulus lupulus Species 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 235000006468 Thea sinensis Nutrition 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000008694 Humulus lupulus Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000009127 Glutaminase Human genes 0.000 description 4
- 108010073324 Glutaminase Proteins 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 244000077233 Vaccinium uliginosum Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 3
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000758706 Piperaceae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 235000015092 herbal tea Nutrition 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000020333 oolong tea Nutrition 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 241000208152 Geranium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 240000009023 Myrrhis odorata Species 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 208000012545 Psychophysiologic disease Diseases 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000019992 sake Nutrition 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 235000019583 umami taste Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- XZKUCJJNNDINKX-HGLHLWFZSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4s)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy]oxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 XZKUCJJNNDINKX-HGLHLWFZSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000007436 Cananga odorata Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 1
- 244000166675 Cymbopogon nardus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 241000269820 Euthynnus affinis Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010069492 Herbal toxicity Diseases 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000008440 Passiflora incarnata Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000513 Santalum album Species 0.000 description 1
- 235000008632 Santalum album Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001622809 Serratia plymuthica Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 1
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 1
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 1
- 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
- 244000284012 Vetiveria zizanioides Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、テアニンと、ハーブ、GABA及びパラチノースからなる群より選ばれる1種又は2種以上を含有することを特徴とする抗ストレス及びリラックス用組成物に関する。 The present invention relates to an anti-stress and relaxation composition comprising theanine and one or more selected from the group consisting of herbs, GABA and palatinose.
現代社会においては、たくさんのストレスに満ちており、例えば、暑さ、寒さ、騒音、渋滞、満員電車での通勤、結婚、子育て等取り巻く自然、社会環境のすべてからストレスが生じている。財団法人健康・体力事業財団の調査によるとストレスを受けた人では、「肩や首筋が凝る」「背中や腰が痛む」「疲れやすい」「前日の疲れが朝まで残っている」「イライラする」といった症状を訴える人が多い。 In modern society, there is a lot of stress, for example, heat, cold, noise, traffic jams, commuting on a crowded train, marriage, child-rearing, and other natural and social environments. According to a survey by the Foundation for Health and Physical Fitness, for those who were stressed, “the shoulders and neck are stiff”, “the back and hips hurt”, “easy to get tired”, “the previous day's fatigue remains until the morning” Many people complain of symptoms such as.
また、人にストレスが負荷されると、下垂体にストレス刺激が伝達され、副腎皮質刺激ホルモン(ACTH)が多く分泌し、副腎皮質からコルチゾールに代表される副腎皮質ホルモン(ステロイド)が血中に放出され免疫力が低下する。一方、ストレス刺激は交感神経系にも伝達され、副腎髄質からアドレナリンまたはノルアドレナリン等のカテコールアミン類が血中に放出され、血管の収縮等様々な薬理作用を引き起こす。我々はこれらストレスを回避するためにリラックスすることが必要である。 In addition, when a person is stressed, stress stimulation is transmitted to the pituitary gland, and a large amount of corticotropin (ACTH) is secreted from the adrenal cortex. Corticosteroids (steroids) typified by cortisol are in the blood. Released and immunity decreases. On the other hand, stress stimuli are also transmitted to the sympathetic nervous system, and catecholamines such as adrenaline or noradrenaline are released from the adrenal medulla into the blood, causing various pharmacological actions such as vasoconstriction. We need to relax to avoid these stresses.
生理心理的状態を判断するには生体反応を観察する手段があり、その一つとして脳波を測定する方法がある。脳から出る微弱な電流を記録した脳波は、周波数範囲によってδ波、θ波、α波、β波に分けられる。その中でもα波は心が落ち着きゆったりとした気分の時に現れるため、リラックスの指標として挙げられる(例えば、非特許文献1参照。)。このように脳波はリラックスの状態を客観的にはかることができる有効な手段として注目されている。このようなα波を出現させる方法として喫煙や(例えば、非特許文献2参照。)、香り(例えば、非特許文献3参照。)が認められている。
また、従来テアニンは玉露の旨み成分として知られ、茶をはじめとする食品の香味及び調味成分として重要でありその需要が高まりつつある。また一方では、テアニンを含めたγ−グルタミル誘導体は、動物・植物体における生理活性物質として知られている。例えば、テアニンはカフェイン中枢興奮作用を抑制する物質であることが知られ(例えば、非特許文献4、5参照。)、その生理活性物質としての有効性が期待されている。
従来より、テアニンの抗ストレス及びリラックス効果は知られており、L−テアニンを有効成分とした交感神経の緊張状態を緩和することにより、ストレスにより生じる精神的及び身体的疾患を予防すること(例えば、特許文献1参照。)が開示されている。更に、テアニンを経口的に摂取することによりα波が増強されリラックス効果が認められている(例えば、非特許文献6、特許文献2参照。)。しかしながら、「L−テアニンのヒトの脳波に及ぼす影響」(非特許文献6)のように、テアニンは全ての人に対しα波のパワー値の増大が認められるわけではない。人はその個人が抱く精神的や身体的な不安として顕在性不安をもっており、それはその人が持っている不安の数ではなく、その不安の状態になり易いか又はなり難いかという傾向を表している。その人々がもっている不安感やその身体的な現れを全体的に評価する方法としてはMAS(Manifest Anxiety Scale:顕在性不安検査)が用いられる。MAS診断によりその不安得点から不安得点の高い高不安群と不安得点の低い低不安群に分類できる。高不安群の特徴としては、抑うつ型、自己不確実型、無力型、対人恐怖症、赤面恐怖症等の性格異常や、また社会に対し顕著に不適応であることが挙げられる。低不安群の特徴としては、外交的な性格、転換ヒステリー等が挙げられる。MAS診断により被験者を低不安群と高不安群に群別してテアニンを投与したところ、正常人群より不安度の高い高不安群では一回投与あたりテアニンの50mgの摂取によりリラックスの指標となるα波の増強が認められたが、不安度の低い低不安群では200mgの摂取においてもほとんどα波の増強が認められていない。
また、セントジョーンズウォートのようなハーブやGABA、パラチノースもリラックスと関係があることが知られている。(例えば、非特許文献7、8、特許文献3参照。)しかしながら、ハーブを含む漢方薬を摂取することにより肝臓や腎臓への機能障害や血小板減少を起こしたりすることが知られている。(例えば、非特許文献9,10、11、12、13参照。)
In order to determine the physiological and psychological state, there is a means for observing a biological reaction, and one of them is a method for measuring an electroencephalogram. An electroencephalogram in which a weak current from the brain is recorded is divided into a δ wave, a θ wave, an α wave, and a β wave depending on the frequency range. Among them, alpha waves appear when the mind feels calm and can be cited as an index of relaxation (see Non-Patent
Conventionally, theanine is known as a delicious ingredient of gyokuro, and is important as a flavor and seasoning ingredient for foods including tea, and its demand is increasing. On the other hand, γ-glutamyl derivatives including theanine are known as physiologically active substances in animals and plants. For example, theanine is known to be a substance that suppresses caffeine central excitability (see, for example, Non-Patent Documents 4 and 5), and is expected to be effective as a physiologically active substance.
Conventionally, the anti-stress and relaxation effects of theanine have been known, and by relieving the sympathetic nervous state of L-theanine as an active ingredient, it prevents mental and physical diseases caused by stress (for example, , See Patent Document 1). Furthermore, by taking theanine orally, α waves are enhanced and a relaxing effect is recognized (for example, see Non-Patent Document 6 and Patent Document 2). However, as shown in “Effect of L-Theanine on Human Brain Waves” (Non-Patent Document 6), theanine does not necessarily show an increase in the power value of α-waves for all people. A person has obvious anxiety as an individual's mental and physical anxiety, which is not the number of anxiety that the person has but represents the tendency to be more or less likely to be in that state of anxiety. Yes. MAS (Manifest Anxiety Scale) is used as a method for evaluating the anxiety and physical appearance of the people as a whole. Based on the MAS diagnosis, the anxiety score can be classified into a high anxiety group with a high anxiety score and a low anxiety group with a low anxiety score. The characteristics of the high anxiety group include personality abnormalities such as depression, self-uncertainty, helplessness, interpersonal phobia, blush phobia, and markedly maladaptation to society. The characteristics of the low anxiety group include diplomatic personality, conversion hysteria and the like. When theanine was administered to the low anxiety group and the high anxiety group according to the MAS diagnosis, in the high anxiety group with a higher degree of anxiety than the normal group, the intake of 50 mg of theanine per dose gave an α wave as an index of relaxation. Although the enhancement was observed, in the hypoxia group with a low degree of anxiety, even when 200 mg was ingested, the enhancement of α waves was hardly observed.
It is also known that herbs such as St. John's wort, GABA, and palatinose are also related to relaxation. (See, for example, Non-Patent Documents 7 and 8, and Patent Document 3.) However, it is known that ingestion of a herbal medicine containing herbs causes dysfunction and thrombocytopenia to the liver and kidney. (For example, refer
テアニンを摂取することによりリラックスの指標であるα波を増強することができるが、人を精神・身体的な徴候として表出される顕在性不安により分類したところ高不安群の被験者ではα波の増強が認められたが、低不安群の被験者においてはα波の増強が認められず全ての人に有効でなかった。 Ingestion of theanine can enhance α-wave, which is an index of relaxation. However, when classified according to overt anxiety expressed as a mental or physical sign, subjects in the high anxiety group have increased α-wave. However, in the subjects in the low anxiety group, α waves were not enhanced and were not effective for all people.
本発明者らは、低不安群の被験者でもリラックス効果が認められる手段について検討した結果、テアニンと、ハーブ、GABA及びパラチノースからなる群より選ばれる1種又は2種以上を併用することにより、テアニンのみではα波増強効果が認められなかった低不安群においてもα波増強効果が認められ、更に高不安群においてはより少ないテアニン量においてα波増強効果が認められることから抗ストレス及びリラックスに有効であることを見いだし、本発明を完成した。テアニンの上記効果は、本発明者らが初めて見いだした新規効果である。 As a result of examining the means by which the subjects in the low anxiety group have a relaxing effect, the present inventors have found that theanine and one or more selected from the group consisting of herbs, GABA and palatinose are used in combination. Even in the low anxiety group where the α wave enhancement effect was not observed by itself, the α wave enhancement effect was observed in the low anxiety group. As a result, the present invention has been completed. The above effect of theanine is a novel effect that the present inventors have found for the first time.
本発明品は、テアニンと、ハーブ、GABA及びパラチノースからなる群より選ばれる1種又は2種以上を併用することにより、テアニンのみではα波増強効果が認められなかった低不安群においても抗ストレス/リラックスの指標であるα波を増強することができ、更に高不安群においてはテアニン単品より少ないテアニン量においてα波増強効果が得られる。 The product of the present invention is a combination of theanine and one or more selected from the group consisting of herbs, GABA, and palatinose, so that anti-stress can be achieved even in hypoxia group where α wave enhancement effect was not observed with theanine alone. The α wave, which is an index of relaxation, can be enhanced, and in the highly anxiety group, the α wave enhancing effect can be obtained with a smaller amount of theanine than the theanine alone.
以下、本発明について詳述する。
本発明に用いられるテアニンとは、茶の葉に含まれているグルタミン酸誘導体で、茶の旨味の主成分であって、呈味を用途とする食品添加物として使用されている。本発明に用いられるテアニンの製造法としては、茶葉から抽出する方法、有機合成反応させてテアニンを得る方法(Chem.Pharm.Bull.,19(7)1301−1307(1971))、グルタミンとエチルアミンの混合物にグルタミナーゼを作用させてテアニンを得る方法(特公平7−55154号)、エチルアミンを含有する培地で茶の培養細胞群を培養し、培養細胞群中のテアニン蓄積量を増加させつつ培養細胞群の増殖促進を図る方法(特開平5−123166号)、また、特公平7−55154号、開平5−123166号におけるエチルアミンをエチルアミン塩酸塩等のエチルアミン誘導体に置き換えてテアニンを得る方法、茶葉から抽出する方法等がありいずれの方法でも良い。ここでいう茶葉とは、緑茶、ウーロン茶、紅茶等が挙げられる。このような方法により得られたテアニンは、L−体、D−体、DL−体いずれも使用可能であるが、中でもL−体は、食品添加物にも認められており、経済的にも利用しやすいため、本発明においては、L−体が好ましい。
本発明に用いるテアニンは精製品(テアニン含量98%以上)、粗精製品(テアニン含量50〜98%)、抽出エキス(テアニン含量10〜50%)等でいずれの形状でも良い。また、市販されているサンテアニン(太陽化学株式会社製)を用いても良い
Hereinafter, the present invention will be described in detail.
The theanine used in the present invention is a glutamic acid derivative contained in tea leaves, which is the main ingredient of the umami of tea and is used as a food additive for the purpose of taste. The theanine used in the present invention includes a method for extracting from tea leaves, a method for obtaining theanine by organic synthesis reaction (Chem. Pharm. Bull., 19 (7) 1301-1307 (1971)), glutamine and ethylamine. A method of obtaining theanine by allowing glutaminase to act on a mixture of the above (Japanese Patent Publication No. 7-55154), culturing a cultured cell group of tea in a medium containing ethylamine, and increasing the amount of theanine accumulated in the cultured cell group A method for promoting the growth of a group (JP-A-5-123166), a method for obtaining theanine by replacing ethylamine with an ethylamine derivative such as ethylamine hydrochloride in JP-B-7-55154 and Kaihei 5-123166, from tea leaves There are methods for extraction, and any method may be used. As used herein, tea leaves include green tea, oolong tea, black tea, and the like. Theanine obtained by such a method can be used in any of the L-form, D-form, and DL-form, but the L-form is also recognized as a food additive, economically. In the present invention, the L-form is preferable because it is easy to use.
The theanine used in the present invention may be a refined product (theanine content of 98% or more), a crude refined product (theanine content of 50 to 98%), an extract extract (theanine content of 10 to 50%) or the like. In addition, commercially available suntheanine (manufactured by Taiyo Kagaku Co., Ltd.) may be used.
本発明に用いられるテアニンの安全性は高く、たとえば、マウスを用いた急性毒性試験において5g/kg経口投与で死亡例がなく、一般状態及び体重等に異常は認められない。また、特にテアニンは茶のうまみ成分として知られているものであり、呈味を用途とする食品添加物としても使用され、食品衛生法上、その添加量に制限はない。しかも、従来の薬物と異なり、テアニンによる副作用は全く認められないので、本発明の組成物によれば、安全かつ効果的に抗ストレス及びリラックス用組成物として使用できる。 Theanine used in the present invention is highly safe. For example, in an acute toxicity test using mice, there is no death due to oral administration of 5 g / kg, and no abnormality is observed in the general state and body weight. In particular, theanine is known as a umami component of tea and is also used as a food additive for flavoring purposes, and there is no limit to the amount of addition in the Food Sanitation Law. Moreover, unlike the conventional drugs, no side effects due to theanine are observed, and therefore the composition of the present invention can be used safely and effectively as an anti-stress and relaxation composition.
本発明におけるハーブとは多数の植物の総称名であり、古来より料理の香りや味付け、薬用、香料、染料、祭事、ドライフラワー、ポプリ等日常生活に利用される植物である。又はブを利用面から分類すると病気の治療等に使われる薬草あるいは薬用植物と、料理等に使われる香草や風味用植物に大別される。 The herb in the present invention is a generic name for many plants, and since ancient times, it is a plant used in daily life such as aroma and seasoning of cooking, medicinal products, fragrances, dyes, festivals, dried flowers and potpourri. Or, when categorized from the viewpoint of utilization, it is roughly divided into medicinal herbs or medicinal plants used for treatment of diseases, and herbs and flavored plants used for cooking.
本発明に用いられるハーブは特に限定されるものではないが、アニス、キャロットシード、クローブ、コリアンダー、サイプレス、シナモン、ジュニパー、ジンジャー、スイートオレンジ、パインニードル、バジル、パチュリ、ビターオレンジ、フェンネル、ブラックペッパー、ベイ、ペパーミント、ベルガモット、マンダリン、ミルラ、レモングラス、グレープフルーツ、シダーウッド、シトロネラ、セージ、タイム、ティートゥリー、バイオレットリーフ、バニラ、ヒソップ、ユーカリ、ライム、レモン、イランイラン、カルダモン、クラリセージ、ジャスミン、ゼラニウム、ブルガリアローズ、ローズ、オリバナム、ラベンダー、カミツレ、ゼラニウム、サンダルウッドネロリ、バーベナ、プチグレン、ベチバー、マージョラム、メリッサ、ローズウッド、オトギリソウ、カワカワ、セイントジョーンズワート、バレリアン、パッションフラワー、ホップ、ラフマ、ブラックコーホッシュ、カモミール、朝鮮人参エキス、レモンバーム、ローズマリー等があげられ、好ましくは抗ストレス効果に有効であるセントジョーンズウォート、バレリアン、パッションフラワー、ホップ、ラフマ、ブラックコーホッシュ、カモミール、朝鮮人参エキス、レモンバーム、ローズマリー等が挙げられる。これらのハーブの形状としては抽出エキス、精油、ハーブティー等で特に限定されるものではない。 The herbs used in the present invention are not particularly limited, but anise, carrot seed, clove, coriander, cypress, cinnamon, juniper, ginger, sweet orange, pine needle, basil, patchouli, bitter orange, fennel, black pepper , Bay, Peppermint, Bergamot, Mandarin, Myrrh, Lemongrass, Grapefruit, Cedarwood, Citronella, Sage, Thyme, Tea Tree, Violet Leaf, Vanilla, Hyssop, Eucalyptus, Lime, Lemon, Ylang Ylang, Cardamom, Clarisage, Jasmine, Geranium , Bulgarian rose, rose, olivenum, lavender, chamomile, geranium, sandalwood neroli, verbena, petit gren, vetiver, marjoram, meri Examples include saury, rosewood, hypericum, kawakawa, saint jones wort, valerian, passion flower, hops, raffma, black cohosh, chamomile, ginseng extract, lemon balm, rosemary, etc. Jones wort, valerian, passion flower, hop, ruffma, black cohosh, chamomile, ginseng extract, lemon balm, rosemary and the like. The shape of these herbs is not particularly limited by extracts, essential oils, herbal teas and the like.
本発明におけるGABAとはγ-アミノ酪酸(γ-amino butyric acid)の略称であり、動植物等広く分布するアミノ酸の一種で、哺乳動物の脳や脊髄に存在する抑制系の神経伝達物質である。GABAは脳の血流を改善し酸素供給量を増加させ脳代謝を亢進させる働きを持つことから、脳卒中や頭部外傷後遺症、脳動脈後遺症による頭痛、耳鳴り、欲求低下等の治療に応用される。またその他の生理効果として、学習能力の向上、腎機能の活性化が知られている。本発明におけるGABAは胚芽米、緑茶、米ぬかの乳酸菌による発酵、グルタミン酸から乳酸菌を用いて発酵することにより得ることができるが、得に限定されるものではない。 GABA in the present invention is an abbreviation for γ-aminobutyric acid and is a kind of amino acid widely distributed in animals and plants, and is a suppressive neurotransmitter present in the brain and spinal cord of mammals. GABA has the function of improving cerebral blood flow, increasing oxygen supply, and accelerating cerebral metabolism, so it can be applied to the treatment of headache, tinnitus, decreased desire, etc. due to sequelae of stroke, head trauma, and cerebral artery sequelae . As other physiological effects, improvement of learning ability and activation of renal function are known. GABA in the present invention can be obtained by fermentation using lactic acid bacteria of germinated rice, green tea, rice bran, or fermenting from glutamic acid using lactic acid bacteria, but is not limited to obtaining.
本発明におけるパラチノース(palatinose)とは、別名イソマルツロース(isomaltulose)ともいい、グルコースがフラクトースにα−1,6−グルコシル結合することによって構成された二糖である。パラチノース一水和物結晶の特性は次に示す通りである。融点は123〜124℃であり、比旋光度は[α]20D+97.2、フェ−リング溶液還元力はグルコースの52%、水100gに対する溶解度は、20℃で38.4g、40℃で78.2g、そして60℃で174.9gである。水溶液の甘味の質は良好で、甘味度はショ糖の約40%である。パラチノースは、天然において蜂蜜又は甘蔗汁中に見出される。また、細菌又は酵母に由来するα−グルコシルトランスフェラーゼ(イソマルチュロース シンターゼ)がショ糖に作用した場合に生じる転移生成物中にも存在する。工業的には、パラチノースは、ショ糖にプロタミノバクター・ルブラン(Protaminobacter rubrum)又はセラチア・プリムチカ(Serratia plymuthica)等の細菌が生み出すα−グルコシルトランスフェラーゼを作用させることにより、ショ糖の大部分がパラチノースに変換される。 The palatinose in the present invention is also called isomaltulose, and is a disaccharide constituted by α-1,6-glucosyl bonding of glucose to fructose. The characteristics of palatinose monohydrate crystals are as follows. The melting point is 123-124 ° C., the specific rotation is [α] 20D + 97.2, the Ferring solution reducing power is 52% of glucose, and the solubility in 100 g of water is 38.4 g at 20 ° C. and 78.40 at 40 ° C. 2 g, and 174.9 g at 60 ° C. The sweetness quality of the aqueous solution is good and the sweetness is about 40% of sucrose. Palatinose is found in nature in honey or sweet potato juice. Moreover, it exists also in the transfer product produced when (alpha) -glucosyltransferase (isomalulose synthase) derived from bacteria or yeast acts on sucrose. Industrially, palatinose is produced by the action of sucrose on α-glucosyltransferase produced by bacteria such as Protaminobacter rubrum or Serratia plymutica, so that most of the sucrose is produced. Converted to palatinose.
抗ストレス及びリラックス効果が期待できるテアニンの摂取量としては、一日あたり0.1mgから10,000mgで、好ましくは1mgから5,000mg、更に好ましくは10mgから1,000mgである。また、併用される各種ハーブとテアニンの比率はハーブ/テアニンで表した場合、セントジョーンズウォートにおいては好ましくは0.1〜20、更に好ましくは2〜6であり、バレリアンにおいては好ましくは0.2〜40、更に好ましくは4〜12であり、パッションフラワーにおいては好ましくは0.2〜80、更に好ましくは5〜13であり、ホップにおいては好ましくは0.1〜10、更に好ましくは1〜4であり、ラフマにおいては好ましくは0.4〜60、更に好ましくは6〜16であり、ブラックコーホッシュにおいては好ましくは0.1〜10、更に好ましくは1〜4であり、カモミールにおいては好ましくは0.4〜60、更に好ましくは6〜16であり、朝鮮人参エキスにおいては好ましくは0.02〜10、更に好ましくは0.4〜2であり、レモンバームにおいては好ましくは0.3〜30、更に好ましくは2〜12であり、ローズマリーにおいては好ましくは0.4〜60、更に好ましくは6〜16である。更に、併用されるGABAとテアニンの比率は好ましくは0.1〜20、更に好ましくは2〜6である。 The intake amount of theanine that can be expected to have an anti-stress and relaxation effect is 0.1 mg to 10,000 mg per day, preferably 1 mg to 5,000 mg, more preferably 10 mg to 1,000 mg. The ratio of various herbs and theanine used in combination is preferably 0.1 to 20, more preferably 2 to 6 in St. John's wort when expressed in herb / theanine, and preferably 0.2 to valerian. -40, more preferably 4-12, preferably 0.2-80 for passionflower, more preferably 5-13, preferably 0.1-10 for hops, more preferably 1-4. In Raffma, it is preferably 0.4 to 60, more preferably 6 to 16, in black cohosh, preferably 0.1 to 10, more preferably 1 to 4, and preferably in chamomile. 0.4 to 60, more preferably 6 to 16, and preferably 0.02 to 10 and more preferably in the ginseng extract. 0.4 to 2, preferably 0.3 to 30 for lemon balm, more preferably 2 to 12, and preferably 0.4 to 60, and more preferably 6 to 16 for rosemary. . Furthermore, the ratio of GABA and theanine used in combination is preferably 0.1 to 20, more preferably 2 to 6.
併用されるパラチノースとテアニンの比は、パラチノース/テアニンで表した場合、好ましくは5〜100、更に好ましくは5〜50であり、かつパラチノースの摂取量は1g以上好ましくは5g以上の量を一度に又は短い時間間隔で摂取されることが好ましい。 The ratio of palatinose and theanine used in combination is preferably 5 to 100, more preferably 5 to 50 when expressed in palatinose / theanine, and the intake of palatinose is 1 g or more, preferably 5 g or more at a time. Or it is preferable to take in a short time interval.
本発明におけるMAS(Manifest Anxiety Scale:顕在性不安検査)診断とは、個人が抱く不安すなわち身体的、精神的な不安で明らかに意識されるものを測定し、その不安の程度を明らかにすることを目的とした診断方法である。この診断テストはテーラーにより不安の程度を測定する目的でMMPI(Minesota multiphasic inventory:ミネソタ多重人格目録)の550の質問項目から選んで検討した結果、MASの50項目を以って質問項目としているものである。日本において用いられているMASは不安尺度50項目以外に、応答の妥当性を吟味する目的で虚構点(Lie Scale)の15項目を交えてあり、合計65項目から構成されている。MASの項目は、原則的に「そう」「ちがう」の2件法で回答され、いずれとも決定できないときのみ「どちらでもない」という回答にまるをつける。被験者は男子大学生、女子大学生、一般男子、一般女子の4つの尺度で評価され、不安得点は不安の程度によりI〜Vの5段階の段階基準に分類される。IIIが標準段階であることを示す。段階IIは不安度がかなり高いことを示し、段階Iは高度の不安を示し、例えば神経症や精神分裂病、躁鬱病あるいは心身症の患者は高得点を示す。また段階Iは不安度がかなり低いことを示している。 The MAS (Manifest Anxiety Scale) diagnosis in the present invention is to measure the anxiety that an individual has, that is, clearly conscious of physical or mental anxiety, and to clarify the degree of the anxiety. This is a diagnostic method for the purpose. This diagnostic test was selected from 550 questions of the MMPI (Minnesota multiphasic inventory) for the purpose of measuring the degree of anxiety by a tailor. It is. The MAS used in Japan has 15 items of imaginary points (Lie Scale) for the purpose of examining the validity of the response in addition to the 50 items of the anxiety scale, and is composed of 65 items in total. In principle, the MAS item is answered in the two cases of “Yes” and “No”, and only when neither of them can be determined, the answer “None” is marked. The subjects are evaluated on four scales: male university students, female university students, general boys, and general girls, and the anxiety score is classified into five grades of I to V according to the degree of anxiety. III indicates the standard stage. Stage II indicates that the degree of anxiety is quite high, and Stage I indicates a high degree of anxiety, for example, patients with neurosis, schizophrenia, manic depression or psychosomatic disorders have high scores. Stage I shows that the degree of anxiety is quite low.
本発明における低不安群とは、上記MAS診断により、段階IV又はVの評価となる人をいい、その特徴としては、その人がストレス状況下においても、ひどく情緒的に休まらない感じをもつ傾向がないことを示し、こうした人は、このような状況下でも平静で混乱しないでいられ、自分がその状況を統御しているかのように感じることが挙げられる。さらに、複雑な学習場面でも高不安群より遂行度は良いと考えられている。
また、高不安群の特徴としては、「身体の訴えが多い。」「大体いつも、興奮していたり落ち着かない感じを持っている。」「集中力に障害がある。」「自信を欠く。」「他人の反応に敏感である。」や「不幸感と無能感を持つ。」が挙げられる。
The low anxiety group in the present invention refers to a person who is evaluated in stage IV or V by the MAS diagnosis, and the characteristic is that the person has a feeling that he / she does not rest severely even under stress. This means that these people can remain calm and unconfused under these circumstances, and feel as if they are managing the situation. Furthermore, it is considered that even in complex learning situations, the performance is better than the high anxiety group.
In addition, the characteristics of the high anxiety group are: “Many physical complaints.” “Generally, I always feel excited and uncomfortable.” “I have difficulty concentrating.” “Lack of confidence.” "Sensitive to other people's reactions" and "Has unhappiness and incompetence."
本発明におけるストレスとは、人間に身体的あるいは心理的な身構えを引き起こさせる事態で、なおかつ心身のバランスをくずす可能性をもった生活上の出来事である。ストレスによってもたらされる反応は感情面、行動面、身体面に現れ、ストレスを受けた場合には個人差はあるが感情面や行動面に何らかの反応があらわれ、身体面では心拍数や呼吸数の増加、血圧の上昇、筋緊張の亢進があらわれる。ストレスの種類としてはストレッサーにより分類され、物理的ストレス、化学的ストレス、生物学的ストレス、心理的ストレス、社会的ストレスに分類される。心理的ストレスは神経症、うつ病、心身症とといった自律神経障害といった精神障害に大きく関与している。現代社会においては心身ストレスが大きくストレスといわれるものは精神的ストレスを意味することが多い。またリラックスとはこのような過剰なストレス反応を緩和することをいう。 The stress in the present invention is a situation that causes a human body to be physically or psychologically and is a life event that has a possibility of losing balance between mind and body. Responses caused by stress appear on the emotional, behavioral, and physical aspects. When stressed, there are individual differences, but some emotional and behavioral reactions appear. On the physical aspect, heart rate and respiratory rate increase. Increased blood pressure, increased muscle tone. The types of stress are classified by stressors, and are classified into physical stress, chemical stress, biological stress, psychological stress, and social stress. Psychological stress is greatly involved in mental disorders such as autonomic disorders such as neurosis, depression and psychosomatic disorders. In modern society, psychosomatic stress is large, and what is called stress often means mental stress. Relaxing refers to alleviating such an excessive stress response.
また、本発明の抗ストレス及びリラックス用組成物に生薬、アミノ酸、ビタミン、ミネラル、その他食品又は医薬品に許容される素材・原料を併用することができる。ここにおいて、使用する生薬とは特に限定されるものではないが、カノコソウ、当帰、芍薬、牡丹、高麗人参等が挙げられる。 In addition, the anti-stress and relaxation composition of the present invention can be used in combination with herbal medicines, amino acids, vitamins, minerals, and other materials and raw materials acceptable for food or medicine. Here, the herbal medicine to be used is not particularly limited, and examples thereof include valerian, toki, glaze, peony, ginseng and the like.
併用するアミノ酸はGABA以外に、例えば、グルタミン、グルタミン酸、イノシン酸、アラニン、アルギニン、アスパラギン酸、スレオニン、セリン、タウリン、チオタウリン、ヒポタウリン等が挙げられるが、これらに限定されるものではない。 In addition to GABA, examples of amino acids to be used in combination include, but are not limited to, glutamine, glutamic acid, inosinic acid, alanine, arginine, aspartic acid, threonine, serine, taurine, thiotaurine, and hypotaurine.
併用するビタミンにおいてはビタミンA、ビタミンB1 、ビタミンB2 、ビタミンB6 、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK、葉酸、ニコチン酸、リポ酸、パントテン酸、ビオチン、ユビキノン、プロスタグランジン等があげられ、これらビタミンの誘導体も含まれるがこれらのみに限定されるものではない。 Among the vitamins used in combination, vitamin A, vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, nicotinic acid, lipoic acid, pantothenic acid, biotin, ubiquinone , Prostaglandins and the like, including derivatives of these vitamins, but are not limited thereto.
併用するミネラルにおいては、カルシウム、鉄、マグネシウム、銅、亜鉛、セレン、カリウム等が挙げられるが、これらに限定されるものではない。 Examples of minerals used in combination include, but are not limited to, calcium, iron, magnesium, copper, zinc, selenium, and potassium.
また、その他、アロエ、ローヤルゼリー、メラトニン、プラセンタ、プロポリス、イソフラボン、大豆レシチン、卵黄レシチン、卵黄油、コンドロイチン、カカオマス、コラーゲン、酢、クロレラ、スピルリナ、イチョウ葉、緑茶、杜仲茶、黄妃茶、ウーロン茶、桑の葉、甜茶、バナバ茶、不飽和脂肪酸、糖アルコールやオリゴ糖等の糖類、ビフィズス菌や紅麹等の菌類、アガリクス茸、姫マツタケ、霊芝、マイタケ等のキノコ類、ブルーベリー、プルーン、ブドウ、オリーブ、うめや柑橘類等の果実類、落花生、アーモンド、ゴマや胡椒等の種実類、ピーマン、唐辛子、ネギ、カボチャ、ウリ、人参、ゴボウ、モロヘイヤ、ニンニク、シソ、ワサビ、トマト、らっきょ、葉菜、芋や豆等の野菜類、ワカメ等の海草類、魚介類、獣鳥鯨肉類、穀類等が使用でき、さらにこれらの抽出物、乾燥品、粗精製品、精製品、加工品、醸造品等も使用できる。 In addition, aloe, royal jelly, melatonin, placenta, propolis, isoflavone, soy lecithin, egg yolk lecithin, egg yolk oil, chondroitin, cacao mass, collagen, vinegar, chlorella, spirulina, ginkgo leaf, green tea, Tochu tea, Huangcha tea, oolong tea Mulberry leaves, strawberry tea, banaba tea, unsaturated fatty acids, sugars such as sugar alcohols and oligosaccharides, fungi such as bifidobacteria and red potatoes, agaricus moth, mushrooms such as princess matsutake, ganoderma lucidum, maitake, blueberries, prunes , Grapes, olives, fruits such as ume and citrus fruits, peanuts, almonds, seeds such as sesame seeds and peppers, peppers, peppers, leeks, pumpkins, cucumbers, carrots, burdock, morohaya, garlic, perilla, wasabi, tomatoes, raccoon, Leafy vegetables, vegetables such as sea bream and beans, seaweeds such as seaweed, seafood, animal and whale meat, S and the like can be used, further these extracts, dry products, crudely purified products, purified products, processed products, brewing Hinto can also be used.
本発明の抗ストレス及びリラックス用組成物の製法は特に限定されるものではなく、テアニンと他の原材料を粉体混合する製法、溶媒中にテアニンと他の原材料を溶かし混合溶液とする製法、またその混合溶液を凍結乾燥する製法、噴霧乾燥する製法等、一般的な食品、医薬品の製法が適用される。 The production method of the anti-stress and relaxation composition of the present invention is not particularly limited, a production method in which theanine and other raw materials are mixed with powder, a production method in which theanine and other raw materials are dissolved in a solvent, and a mixed solution, General food and pharmaceutical production methods, such as a production method of freeze-drying the mixed solution and a production method of spray drying, are applied.
また、本発明品である抗ストレス及びリラックス用組成物を食品又は医薬品として摂取するにはテアニンと、ハーブ、GABA及びパラチノースからなる群より選ばれる1種又は2種以上を含有する溶液、懸濁物、粉末、固体成形物等の形態であれば良く特に限定するものではない。より具体的には、練り製品、大豆加工品、調味料、ムース、ゼリー、冷菓、飴、チョコレート、ガム、クラッカー、ケーキ、パン、スープ、コーヒー、ココア、緑茶、ウーロン茶、紅茶、ハーブティー等の茶類、濃縮果汁、濃縮還元ジュース、ストレートジュース、果実ミックスジュース、果粒入り果実ジュース、果汁入り飲料、果実・野菜ミックスジュース、野菜ジュース、炭酸飲料、清涼飲料、乳飲料、日本酒、ビール、ワイン、カクテル、焼酎、ウイスキー等の飲料、乳製品、酒、錠剤、カプセル、医薬品等が挙げられる。 Moreover, in order to ingest the anti-stress and relaxation composition of the present invention as a food or pharmaceutical, a solution or suspension containing theanine and one or more selected from the group consisting of herbs, GABA and palatinose There is no particular limitation as long as it is in the form of a product, a powder, a solid molded product or the like. More specifically, kneaded products, processed soybean products, seasonings, mousse, jelly, frozen desserts, strawberries, chocolate, gum, crackers, cakes, bread, soup, coffee, cocoa, green tea, oolong tea, black tea, herbal tea, etc. Concentrated juice, Concentrated juice, Straight juice, Fruit mix juice, Fruit juice with fruits, Fruit juice drink, Fruit / vegetable juice, Vegetable juice, Carbonated drink, Soft drink, Milk drink, Japanese sake, Beer, Wine, Cocktail And beverages such as shochu and whiskey, dairy products, sake, tablets, capsules, and pharmaceuticals.
また、医薬品としての剤形は、内服薬、注射薬、貼付薬、座薬、吸入薬等が挙げられる。内服薬は、従来使用されている錠剤、カプセル、粉末剤、顆粒剤、ドリンク剤等によって摂取されるものである。注射薬は、筋肉注射、皮内注射、皮下注射、静脈注射等によって体内に注入されるものである。また、貼付薬は従来使用されている軟膏に混合することにより体内に吸収させるものである。座薬は、従来使用されるカカオ脂、グリセロゼラチン、ステアリン酸ナトリウム、プロピレングリコールモノステアレート等と混合することにより体内に吸収させるものである。吸入薬は、従来の方法により吸入させるものであって、例えば、水蒸気又は空気の中に発明品を加えることにより鼻孔あるいは口腔より体内に吸収されるものである。 Examples of pharmaceutical dosage forms include internal medicines, injections, patches, suppositories, and inhalants. The internal medicine is ingested by conventionally used tablets, capsules, powders, granules, drinks and the like. An injection is injected into the body by intramuscular injection, intradermal injection, subcutaneous injection, intravenous injection or the like. A patch is absorbed into the body by mixing with a conventionally used ointment. Suppositories are absorbed into the body by mixing with cocoa butter, glycerogelatin, sodium stearate, propylene glycol monostearate and the like conventionally used. An inhaled drug is inhaled by a conventional method and is absorbed into the body from the nostril or oral cavity, for example, by adding the invention product to water vapor or air.
以下、実施例及び試験例により本発明をより詳細に説明するが、本発明は当該実施例及び試験例に限定するものではない。 Hereinafter, although an example and a test example explain the present invention in detail, the present invention is not limited to the example and a test example concerned.
実施例1 酵素法によるテアニンの製造
0.3Mグルタミン及び1.5M塩酸エチルアミンを0.05Mホウ酸緩衝液(pH11)中、0.3Uグルタミナーゼ(市販品)存在下にて30℃ 22時間反応させ225nmolのテアニンを得た。次いで、反応液をDowex 50×8、Dowex 1×2カラムクロマトグラフィー(共に室町化学工業(株)製)にかけ、これをエタノール処理することにより、反応液から目的物質を単離し、8.5gのテアニンを得た。
Example 1 Production of Theanine by Enzymatic Method 0.3 M glutamine and 1.5 M ethylamine were reacted in 0.05 M borate buffer (pH 11) in the presence of 0.3 U glutaminase (commercially available) at 30 ° C. for 22 hours. 225 nmol of theanine was obtained. Next, the reaction solution was subjected to Dowex 50 × 8 and
当該物質のテアニンの確認は、この単離物質をアミノ酸アナライザー(日立製作所株式会社製)、ペーパークロマトグラフィーにかけ、標準物質と同じ挙動を示すことにより確認した。塩酸又はグルタミナーゼで加水分解処理を行うと、1:1の割合で、グルタミン酸とエチルアミンを生じた。このように、単離物質がグルタミナーゼによって加水分解されたことから、エチルアミンがグルタミン酸のγ位に結合していたことが示される。また、加水分解で生じたグルタミン酸がL−体であることも、グルタミン酸デヒドロゲナーゼにより確認した。 Confirmation of theanine of the substance was confirmed by subjecting the isolated substance to an amino acid analyzer (manufactured by Hitachi, Ltd.) and paper chromatography and exhibiting the same behavior as the standard substance. Hydrolysis with hydrochloric acid or glutaminase produced glutamic acid and ethylamine in a 1: 1 ratio. Thus, the isolated substance was hydrolyzed by glutaminase, indicating that ethylamine was bound to the γ position of glutamic acid. It was also confirmed by glutamate dehydrogenase that glutamic acid generated by hydrolysis was L-form.
実施例2 テアニンの茶葉からの抽出
茶(Camellia sinensis)葉10kgを熱水で抽出後、カチオン交換樹脂(室町化学工業(株)製 Dowex HCR W−2)に通し、1N NaOHにより溶出した。溶出画分を活性炭(二村化学工業(株)製太閤活性炭 SG)に通し、15%エタノールによる溶出画分をRO膜(日東電工(株)製 NTR 729 HF)を用いて濃縮し、カラムクロマトグラフィーにて精製し、更に再結晶を行い、24.8gのテアニンを得た。
Example 2 Extraction of Teanin from
なお、以下における各試験及び各組成物の製造にはテアニン(商品名:サンテアニン、太陽化学株式会社製)を用いた。 Theanine (trade name: Suntheanine, manufactured by Taiyo Kagaku Co., Ltd.) was used for the following tests and the production of each composition.
試験例1 テアニン飲用による高不安群及び低不安群のα波出現量の比較
試験に参加する被験者については、大学生82人に協力してもらい、MAS調査票(日本版MMPI:三京房製)により顕在性不安傾向を調べ、不安傾向の高い高不安群の14名と不安傾向の低い低不安群の35人を選定した。
Test example 1 Comparison of the amount of alpha wave appearance between the high anxiety group and the low anxiety group due to drinking theanine About the subjects participating in the test, 82 university students cooperated, and MAS questionnaire (Japan version MMPI: manufactured by Sankyobo) We examined the obvious anxiety tendency and selected 14 people in the high anxiety group with high anxiety tendency and 35 persons in the low anxiety group with low anxiety tendency.
また、α波の測定はブレイン・インターフェース(以下、BMIと略す;能力開発研究所製)を用いて測定した。BMIは額2カ所に電極を装着し、耳との電位差を測定することにより脳波測定を行う方法である。測定は当社研究所内の外部遮断された部屋(25℃、40ルクス)で行い、試験区以外の食品が脳波に影響するのを防ぐため、試験前2時間は絶食とした。脳波測定は安静時の脳波を15分間測定し、その後試験飲料を飲用後1時間測定した。解析は安静時及び飲用後1時間の5分毎のα波積算値を平均し、安静時の脳波を1.0とした比として求めた。 The α wave was measured using a brain interface (hereinafter abbreviated as BMI; manufactured by Ability Development Laboratory). BMI is a method of measuring an electroencephalogram by mounting electrodes on two foreheads and measuring a potential difference from the ear. The measurement was performed in an externally shielded room (25 ° C, 40 lux) in our laboratory, and food was fasted for 2 hours before the test in order to prevent food outside the test area from affecting the electroencephalogram. In the electroencephalogram measurement, the electroencephalogram at rest was measured for 15 minutes, and then the test beverage was measured for 1 hour after drinking. In the analysis, the α wave integrated values every 5 minutes at rest and 1 hour after drinking were averaged, and the ratio was determined as a ratio with the brain wave at rest being 1.0.
上記で選定した高不安群14人及び低不安群35人に、サンテアニン10、25、50及び200mgをカプセルに封入したものを飲用してもらい、α波の測定を行った。結果を図1、図2に示す。図1、図2より明らかなように高不安群では50mg、200mgのテアニン含有カプセルを飲用した時α波の増加が認められたが、低不安群ではテアニン摂取におけるα波の増加は若干認められるのみであった。
The 14 selected high anxiety groups and 35 low anxiety groups were allowed to drink
試験例2 高不安群及び低不安群における各種ハーブエキス、GABA及びパラチノースのα波出現量の比較
試験例1で選定した高不安群14人及び低不安群35人に、セントジョーンズウォート(常盤植物化学研究所製)200mg、バレリアン(アスク薬品製)400mg、パッションフラワー(常盤植物化学研究所製)450mg、ホップ(日本粉末薬品製)100mg、ラフマ(常盤植物化学研究所製)500mg、ブラックコーホッシュ(皇漢薬品研究所)100mg、カモミール(日本粉末薬品製)500mg、朝鮮人参エキス(インデナジャパン製)50mg、レモンバーム(日本粉末薬品製)300mg、ローズマリー(公知貿易製)500mg、GABA含有エキス(5%含有、オリザ油化株式会社製)200mgをカプセルに封入したもの又はパラチノース(新三井製糖株式会社製)1gを水100mlに溶解したものを飲用してもらい、試験例1の方法でα波の測定を行った。結果を図3、図4に示す。図3、図4より明らかなように高不安群及び低不安群においてもα波の増強は認められなかった。
Test Example 2 Comparison of α-wave Appearance Levels of Various Herbal Extracts, GABA, and Palatinose in High Anxiety Group and Low Anxiety Group In 14 high anxiety groups and 35 low anxiety groups selected in Test Example 1, St. John's wort (tokiwa plant) Chemical Laboratory) 200 mg, Valerian (Ask Pharmaceutical) 400 mg, Passion Flower (Tokiwa Plant Chemistry Laboratory) 450 mg, Hops (Nippon Powder Chemicals) 100 mg, Ruffa (Tokiwa Plant Chemical Research Laboratory) 500 mg, Black Cohosh (Imperial Pharmaceutical Research Laboratories) 100mg, Chamomile (Nippon Powder Pharmaceutical) 500mg, Ginseng Extract (Indena Japan) 50mg, Lemon Balm (Nippon Powder Chemical) 300mg, Rosemary (Known Trade) 500mg, GABA-containing extract ( 5% containing, manufactured by Oriza Oil Chemical Co., Ltd.) 200mg What was encapsulated in the water or one in which 1 g of palatinose (manufactured by Shin Mitsui Sugar Co., Ltd.) was dissolved in 100 ml of water was drunk, and α waves were measured by the method of Test Example 1. The results are shown in FIGS. As is clear from FIGS. 3 and 4, no enhancement of α waves was observed in the high anxiety group and the low anxiety group.
試験例3 高不安群及び低不安群におけるテアニンとセントジョーンズウォート又はGABAのα波出現量の比較
試験例1で選定した高不安群14人及び低不安群35人に、テアニンとセントジョーンズウォート(常盤植物化学研究所製)200mg又はGABA含有エキス(5%含有、オリザ油化株式会社製)200mgをカプセルに封入したものを飲用してもらい、試験例1の方法でα波の測定を行った。結果を図5、図6に示す。図5、図6より明らかなように低不安群及び高不安群において共にテアニン単独の投与量では認められなかったα波の増強がハーブ、GABAの併用により認められた。
Test Example 3 Comparison of α-wave Appearance of Theanine and St. John's Wort or GABA in High Anxiety Group and Low Anxiety Group Theanine and St. John's Wort (35 people selected in Test Example 1 and 35 low anxiety groups) Tokiwa Phytochemical Laboratories Inc.) 200 mg or GABA-containing extract (5% contained, manufactured by Oriza Oil Chemical Co., Ltd.) 200 mg encapsulated in a capsule was used to measure α waves by the method of Test Example 1. . The results are shown in FIGS. As is clear from FIG. 5 and FIG. 6, in both the low anxiety group and the high anxiety group, the enhancement of α waves, which was not observed with the dose of theanine alone, was recognized by the combined use of herbs and GABA.
試験例4 低不安群におけるテアニンとハーブエキス、GABA及びパラチノースのα波出現量の比較
試験例1で選定した低不安群35人に、テアニン25mgとセントジョーンズウォート(常盤植物化学研究所製)200mg、バレリアン(アスク薬品製)400mg、パッションフラワー(常盤植物化学研究所製)450mg、ホップ(日本粉末薬品製)100mg、ラフマ(常盤植物化学研究所製)500mg、ブラックコーホッシュ(皇漢薬品研究所)100mg、カモミール(日本粉末薬品製)500mg、朝鮮人参エキス(インデナジャパン製)50mg、レモンバーム(日本粉末薬品製)300mg、ローズマリー(公知貿易製)500mg、GABA含有エキス(5%含有、オリザ油化株式会社製)200mgをカプセルに封入したもの又はパラチノース(新三井製糖株式会社製)1gを水100mlに溶解したものを飲用してもらい、試験例1の方法でα波の測定を行った。結果を図7に示す。図7より明らかなように低不安群においてテアニンと各種ハーブ、GABA、パラチノースの併用によりα波の増強が認められた。
Test Example 4 Comparison of Appearance of α-waves of Theanine and Herb Extract, GABA and Palatinose in Hypoxic Group 35
実施例3 テアニン及びハーブの配合粉末剤
テアニン配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を混合、テアニン配合粉末剤を製造した。
テアニン及びセントジョーンズウォート配合粉末剤
テアニン 11.1%(2.5kg)
セントジョーンズウォート 88.9%(20.0kg)
合計 100%(22.5kg)
上記配合粉末剤を試験例1で選定した低不安群35人に225mgをカプセルに封入したものを飲用してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Example 3 Theanine and Herb Formulation Powder As an example of the theanine formulation antistress and relaxation composition, the following raw materials were mixed to produce a theanine formulation powder.
Theanine and St. John's Wort Combination Powder Theanine 11.1% (2.5kg)
St. John's wort 88.9% (20.0kg)
Total 100% (22.5kg)
35 people with low anxiety who selected the above-mentioned blended powder in Test Example 1 were allowed to drink 225 mg encapsulated capsules and measured α waves. As a result, α waves were found to be stronger than those at rest.
実施例4 テアニン、ハーブ及びGABAの配合剤
テアニン配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を混合、テアニン配合剤を製造した。
テアニン、セントジョーンズウォート及びGABA配合剤
テアニン 5.88%(2.5kg)
セントジョーンズウォート 47.06%(20.0kg)
GABA 47.06%(20.0kg)
合計 100%(42.5kg)
上記配合剤を試験例1で選定した低不安群35人に425mgをカプセルに封入したものを飲用してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Example 4 Combination of Theanine, Herb and GABA As an example of the anti-stress and relaxation composition containing theanine, the following raw materials were mixed to produce a theanine combination.
Theanine, St. John's wort and GABA combination agent Theanine 5.88% (2.5 kg)
St. John's wort 47.06% (20.0kg)
GABA 47.06% (20.0kg)
Total 100% (42.5kg)
35 people with low anxiety who selected the above combination in Test Example 1 were allowed to drink what was encapsulated in 425 mg, and when α waves were measured, an increase in α waves was observed compared to rest.
実施例5 テアニン及びハーブ、GABA配合錠剤の製造
テアニン配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を混合後打錠し、テアニン配合錠剤を製造した。
テアニンとセントジョーンズウォート配合錠剤
フロストシュガー 65%(0.4875g)
実施例3の配合粉末剤 30%(0.225g)
ショ糖脂肪酸エステル 1%(0.0075g)
香料(レモンフレーバー) 4%(0.03g)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、常法に従って、造粒後に、1粒0.75gとなるように打錠した。
Example 5 Production of tablets containing theanine, herbs and GABA As an example of the theanine-containing anti-stress and relaxation composition, the following raw materials were mixed and then tableted to produce theanine-containing tablets.
Tablets containing theanine and St. John's wort Frost sugar 65% (0.4875 g)
Compound powder of Example 3 30% (0.225 g)
Sucrose
Fragrance (lemon flavor) 4% (0.03g)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation according to the conventional method.
テアニンとバレリアン配合錠剤
フロストシュガー 38.4%(0.2875g)
テアニン 3.3%(0.025g)
バレリアン 53.3%(0.4g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03g)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and valerian Frost sugar 38.4% (0.2875 g)
Theanine 3.3% (0.025g)
Valerian 53.3% (0.4g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03g)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとパッションフラワー配合錠剤
フロストシュガー 31.7%(0.2375g)
テアニン 3.3%(0.025g)
パッションフラワー 60.0%(0.45g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03g)
合計 100% (0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and passion flower Frost sugar 31.7% (0.2375 g)
Theanine 3.3% (0.025g)
Passion flower 60.0% (0.45g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03g)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとホップ配合錠剤
フロストシュガー 78.4%(0.5875g)
テアニン 3.3%(0.025g)
ホップ 13.3%(0.1g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and hops Frost sugar 78.4% (0.5875 g)
Theanine 3.3% (0.025g)
Hop 13.3% (0.1g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとラフマ配合錠剤
フロストシュガー 25.0%(0.1875g)
テアニン 3.3%(0.025g)
ラフマ 66.7%(0.5g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and rafma Frost sugar 25.0% (0.1875g)
Theanine 3.3% (0.025g)
Rafuma 66.7% (0.5g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとブラックコーホッシュ配合錠剤
フロストシュガー 78.4%(0.5875g)
テアニン 3.3%(0.025g)
ブラックコーホッシュ 13.3%(0.1g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03g)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and black cohosh Frost sugar 78.4% (0.5875 g)
Theanine 3.3% (0.025g)
Black cohosh 13.3% (0.1 g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03g)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとカモミール配合錠剤
フロストシュガー 25.0%(0.1875g)
テアニン 3.3%(0.025g)
カモミール 66.7%(0.5g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and chamomile Frost sugar 25.0% (0.1875g)
Theanine 3.3% (0.025g)
Chamomile 66.7% (0.5g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンと朝鮮人参エキス配合錠剤
フロストシュガー 85.0%(0.6375g)
テアニン 3.3%(0.025g)
朝鮮人参エキス 6.7%(0.05g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and ginseng extract Frost sugar 85.0% (0.6375g)
Theanine 3.3% (0.025g)
Ginseng extract 6.7% (0.05g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとレモンバーム配合錠剤
フロストシュガー 51.7%(0.3875g)
テアニン 3.3%(0.025g)
レモンバーム 40.0%(0.3g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and lemon balm Frost sugar 51.7% (0.3875 g)
Theanine 3.3% (0.025g)
Lemon balm 40.0% (0.3g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとローズマリー配合錠剤
フロストシュガー 25.0%(0.1875g)
テアニン 3.3%(0.025g)
ローズマリー 66.7%(0.5g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03%)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and rosemary Frost sugar 25.0% (0.1875g)
Theanine 3.3% (0.025g)
Rosemary 66.7% (0.5g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03%)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
テアニンとGABA配合錠剤
フロストシュガー 65.0%(0.4875g)
テアニン 3.3%(0.025g)
GABA 26.7%(0.2g)
ショ糖脂肪酸エステル 1.0%(0.0075g)
香料(レモンフレーバー) 4.0%(0.03g)
合計 100%(0.75g)
すなわち、上記配合に従って各原料を混合し、造粒後に、1粒0.75gとなるように打錠した。
Tablets containing theanine and GABA Frost sugar 65.0% (0.4875g)
Theanine 3.3% (0.025g)
GABA 26.7% (0.2g)
Sucrose fatty acid ester 1.0% (0.0075g)
Fragrance (lemon flavor) 4.0% (0.03g)
Total 100% (0.75g)
That is, each raw material was mixed according to the said mixing | blending, and it tableted so that it might become 0.75g of 1 grain after granulation.
参考例1 テアニン及びハーブ配合キャンディーの製造
テアニン及びハーブ配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を用いてテアニン及びハーブ配合キャンディーを製造した。
グラニュー糖 52kg
水飴 23kg
実施例3の配合粉末剤 22.5kg
香料(レモンフレーバー) 0.05kg
50%酒石酸 1kg
水 30kg
グラニュー糖を水20kgに溶解しながら110℃まで加熱し、テアニン及びセントジョーンズウォートを溶解した残りの水10kgと水飴を加えて、145℃まで温度を上げた。火を止め、50%酒石酸を添加し混合した。75〜80℃まで冷却し、成形ローラーで成形し、一粒3.5gのテアニン配合キャンディーを調整した。
上記配合キャンディー一粒を試験例1で選定した低不安群35人に摂取してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Reference Example 1 Production of a candy containing theanine and herbs As an example of a composition for anti-stress and relaxation containing theanine and herbs, a candy containing theanine and herbs was produced using the following raw materials.
Granulated sugar 52kg
Minamata 23kg
Formulation powder of Example 3 22.5 kg
Fragrance (lemon flavor) 0.05kg
50% tartaric acid 1kg
30 kg of water
While dissolving granulated sugar in 20 kg of water, the mixture was heated to 110 ° C., the remaining 10 kg of water in which theanine and St. John's wort were dissolved, and syrup were added, and the temperature was raised to 145 ° C. The fire was turned off and 50% tartaric acid was added and mixed. It cooled to 75-80 degreeC, and it shape | molded with the shaping | molding roller, and prepared 3.5 g of theanine compounding candy of 1 grain.
One of the above blended candy was ingested by 35 low anxiety groups selected in Test Example 1 and measured for α waves. As a result, an increase in α waves was observed as compared to rest.
参考例2 テアニン及びハーブ配合ブルーベリー飲料の製造
テアニン及びハーブ配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を用いてテアニン配合飲料を製造した。
果糖ブドウ糖 12kg
ブルーベリー濃縮果汁 1kg
1/5透明レモン果汁 0.4kg
クエン酸Na 0.05kg
50%クエン酸Na(結晶) pH調整用
実施例3の配合粉末剤 0.225kg
香料(ブルーベリーフレーバー) 0.05kg
水 適量
全量 100kg
果糖ブドウ糖、ブルーベリー濃縮果汁、1/5透明レモン果汁、クエン酸Na及びテアニン及びセントジョーンズウォートを水に加え攪拌溶解した。50%クエン酸Na(結晶)を用いpH3.1に調整し、95℃まで昇温後香料を加えて100mlに充填して冷却し、テアニン及びハーブ配合ブルーベリー飲料を製造した。
上記配合テアニン及びハーブ配合ブルーベリー飲料を試験例1で選定した低不安群35人に摂取してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Reference Example 2 Production of Blueberry Beverage Blended with Theanine and Herb As an example of the anti-stress and relaxation composition blended with theanine and herb, a theanine blended beverage was produced using the following raw materials.
Fructose glucose 12kg
Blueberry concentrated fruit juice 1kg
1/5 clear lemon juice 0.4kg
0.05 kg of sodium citrate
50% Na citrate (crystal) for pH adjustment Formulation powder of Example 3 0.225 kg
Fragrance (blueberry flavor) 0.05kg
Water proper amount 100kg
Fructose glucose, blueberry concentrated juice, 1/5 clear lemon juice, Na citrate, theanine and St. John's wort were added to water and dissolved by stirring. The pH was adjusted to 3.1 using 50% Na citrate (crystal), heated to 95 ° C., added with fragrance, filled in 100 ml and cooled to produce a blueberry beverage containing theanine and herbs.
The above-described blended theanine and herb blended blueberry drink were ingested by 35 low anxiety groups selected in Test Example 1, and α waves were measured. As a result, α waves were found to be stronger than those at rest.
参考例3 テアニン及びハーブ配合チューインガムの作成
テアニン及びハーブ配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を混合してチューインガムを製造した。
ガムベース 20kg
粉糖 74.3kg
実施例3の配合粉末剤 5.7kg
合計 100kg
上記原料を混合して均一になるまで混練し、得られた混練物を50℃に保温しながら押出機でシート状に押出し、さらに圧延ローラーで所定の厚さのシートとし、20mm×75mmの大きさに裁断し、一枚3.5gのチューインガムを製造した。
上記配合テアニン及びハーブ配合チューインガムを試験例1で選定した低不安群35人に摂取してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Reference Example 3 Preparation of Chean Gum Combined with Theanine and Herb As an example of the anti-stress and relaxation composition combined with theanine and herb, the following raw materials were mixed to produce chewing gum.
20kg gum base
Powdered sugar 74.3kg
Formulation powder of Example 3 5.7 kg
Total 100kg
The raw materials are mixed and kneaded until uniform, and the resulting kneaded product is extruded into a sheet shape with an extruder while keeping the temperature at 50 ° C., and is further formed into a sheet with a predetermined thickness with a rolling roller, and has a size of 20 mm × 75 mm. This was cut into 3.5 g chewing gum.
When the above-described blended theanine and herbal blended chewing gum were ingested by 35 low anxiety groups selected in Test Example 1 and α-waves were measured, an increase in α-waves was observed compared to rest.
参考例4 テアニン及びパラチノース配合ブルーベリー飲料の製造
テアニン及びパラチノース配合抗ストレス及びリラックス用組成物の1例として、次に示す原料を用いてテアニン配合飲料を製造した。
果糖ブドウ糖 11kg
パラチノース 1kg
ブルーベリー濃縮果汁 1kg
1/5透明レモン果汁 0.4kg
クエン酸Na 0.05kg
50%クエン酸Na(結晶) pH調整用
テアニン 0.2kg
香料(ブルーベリーフレーバー) 0.05kg
水 適量
全量 100kg
果糖ブドウ糖、パラチノース、ブルーベリー濃縮果汁、1/5透明レモン果汁、クエン酸Na及びテアニンを水に加えて攪拌溶解した。50%クエン酸Na(結晶)を用いpH3.1に調製し、95℃まで昇温後香料を加えて100mlに充填して冷却し、テアニン及びパラチノース配合ブルーベリー飲料を製造した。
上記配合テアニン及びパラチノース配合ブルーベリー飲料を試験例1で選定した低不安群35名に摂取してもらい、α波の測定を行ったところ安静時に比べα波の増強が認められた。
Reference Example 4 Production of Blueberry Beverage Blended with Theanine and Palatinose As an example of the anti-stress and relaxation composition blended with theanine and palatinose, a theanine blended beverage was produced using the following raw materials.
Fructose glucose 11kg
Palatinose 1kg
Blueberry concentrated fruit juice 1kg
1/5 clear lemon juice 0.4kg
0.05 kg of sodium citrate
50% Na citrate (crystal) pH adjustment theanine 0.2kg
Fragrance (blueberry flavor) 0.05kg
Water proper amount 100kg
Fructose glucose, palatinose, blueberry concentrated fruit juice, 1/5 transparent lemon juice, Na citrate and theanine were added to water and dissolved by stirring. The mixture was adjusted to pH 3.1 using 50% Na citrate (crystal), heated to 95 ° C., added with fragrance, filled in 100 ml, cooled, and a blueberry beverage containing theanine and palatinose was produced.
The above-described blended theanine and palatinose blended blueberry drink were ingested by 35 low anxiety groups selected in Test Example 1, and α waves were measured. As a result, enhancement of α waves was observed compared to rest.
本発明の実施態様ならびに目的生成物を挙げれば以下の通りである。
(1)テアニンおよびGABAを含有することを特徴とする抗ストレス及びリラックス用組成物
(2)テアニンおよびパラチノースを含有することを特徴とする抗ストレス及びリラックス用組成物
(3)テアニンおよびセントジョーンズウォートを含有することを特徴とする抗ストレス及びリラックス用組成物
(4)テアニンおよびバレリアンを含有することを特徴とする抗ストレス及びリラックス用組成物
(5)テアニンおよびパッションフラワーを含有することを特徴とする抗ストレス及びリラックス用組成物
(6)テアニンおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(7)テアニンおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(8)テアニン、セントジョーンズウォートおよびバレリアンを含有することを特徴とする抗ストレス及びリラックス用組成物
(9)テアニン、セントジョーンズウォートおよびパッションフラワーを含有することを特徴とする抗ストレス及びリラックス用組成物
(10)テアニン、セントジョーンズウォートおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(11)テアニン、セントジョーンズウォートおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(12)テアニン、バレリアンおよびパッションフラワーを含有することを特徴とする抗ストレス及びリラックス用組成物
(13)テアニン、バレリアンおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(14)テアニン、バレリアンおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(15)テアニン、パッションフラワーおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(16)テアニン、パッションフラワーおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(17)テアニン、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(18)テアニン、セントジョーンズウォート、バレリアンおよびパッションフラワーを含有することを特徴とする抗ストレス及びリラックス用組成物
(19)テアニン、セントジョーンズウォート、バレリアンおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(20)テアニン、セントジョーンズウォート、バレリアンおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(21)テアニン、セントジョーンズウォート、パッションフラワーおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(22)テアニン、セントジョーンズウォート、パッションフラワーおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(23)テアニン、セントジョーンズウォート、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(24)テアニン、バレリアン、パッションフラワーおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(25)テアニン、バレリアン、パッションフラワーおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(26)テアニン、パッションフラワー、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(27)テアニン、セントジョーンズウォート、バレリアン、パッションフラワーおよびカモミールを含有することを特徴とする抗ストレス及びリラックス用組成物
(28)テアニン、セントジョーンズウォート、バレリアン、パッションフラワーおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(29)テアニン、セントジョーンズウォート、バレリアン、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(30)テアニン、セントジョーンズウォート、パッションフラワー、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(31)テアニン、バレリアン、パッションフラワー、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(32)テアニン、セントジョーンズウォート、バレリアン、パッションフラワー、カモミールおよびレモンバームを含有することを特徴とする抗ストレス及びリラックス用組成物
(33)前記(3)〜(32)いずれか記載の抗ストレス及びリラックス用組成物とパラチノースを含有することを特徴とする抗ストレス及びリラックス用組成物
(34)前記(2)〜(33)いずれか記載の抗ストレス及びリラックス用組成物とGABAを含有することを特徴とする抗ストレス及びリラックス用組成物
The embodiment of the present invention and the target product are as follows.
(1) Anti-stress and relaxation composition characterized by containing theanine and GABA (2) Anti-stress and relaxation composition characterized by containing theanine and palatinose (3) Theanine and St. John's wort (4) A composition for anti-stress and relaxation characterized by containing a theanine and valerian (5) A composition for containing a theanine and passion flower (6) Antistress and relaxation composition characterized by containing theanine and chamomile (7) Antistress and relaxation composition characterized by containing theanine and lemon balm (8) Theanine, cent Anti-stress and relaxation composition characterized by containing Jones wort and valerian (9) Anti-stress and relaxing composition characterized by containing theanine, St. John's wort and passion flower (10) Theanine, Anti-stress and relaxation composition characterized by containing St. John's wort and chamomile (11) Anti-stress and relaxation composition characterized by containing St. John's wort and lemon balm (12) Theanine, Anti-stress and relaxation composition characterized by containing valerian and passion flower (13) Anti-stress and relaxation composition characterized by containing theanine, valerian and chamomile ( 4) Anti-stress and relaxation composition characterized by containing theanine, valerian and lemon balm (15) Anti-stress and relaxation composition characterized by containing theanine, passion flower and chamomile (16) Theanine Anti-stress and relaxing composition characterized by containing passion flower and lemon balm (17) Anti-stress and relaxing composition characterized by containing theanine, chamomile and lemon balm (18) Theanine, St. Johns Anti-stress and relaxation composition characterized by containing wort, valerian and passion flower (19) Anti-stress characterized by containing theanine, St. John's wort, valerian and chamomile TRES AND RELAXING COMPOSITION (20) Anti-stress and relaxing composition characterized by containing theanine, St. John's wort, valerian and lemon balm (21) Containing theanine, St. John's wort, passion flower and chamomile (22) Anti-stress and relaxing composition comprising theanine, St. John's wort, passion flower and lemon balm (23) Theanine, St. John's wort, chamomile and Anti-stress and relaxing composition characterized by containing lemon balm (24) Anti-stress characterized by containing theanine, valerian, passion flower and chamomile (25) Anti-stress and relaxation composition characterized by containing theanine, valerian, passion flower and lemon balm (26) characterized by containing theanine, passion flower, chamomile and lemon balm Anti-stress and relaxing composition (27) Anti-stress and relaxing composition comprising theanine, St. John's wort, valerian, passion flower and chamomile (28) Theanine, St. John's wort, valerian, passion flower And anti-stress and relaxation composition characterized by containing lemon balm (29) containing theanine, St. John's wort, valerian, chamomile and lemon balm Anti-stress and relaxation composition characterized by (30) Anti-stress and relaxation composition characterized by containing theanine, St. John's wort, passion flower, chamomile and lemon balm (31) Theanine, valerian and passion flower (32) Anti-stress and relaxation composition comprising theanine, St. John's wort, valerian, passion flower, chamomile and lemon balm Item (33) Antistress and relaxation composition according to any one of (3) to (32) and palatinose (34) (2) to (3) 3) The composition for anti-stress and relaxation characterized by containing the anti-stress and relaxation composition in any one, and GABA
本発明によれば、テアニンのみではα波増強効果が認められなかった低不安群においても抗ストレス/リラックスの指標であるα波を増強することができ、更に高不安群においてはテアニン単品より少ないテアニン量においてα波増強効果が得られるため、食品や医薬品産業に大いに貢献するものである。 According to the present invention, α waves, which are an index of anti-stress / relaxation, can be enhanced even in the low anxiety group in which the α wave enhancing effect was not observed with theanine alone, and in the high anxiety group, the number of theanine is less than that of the single product. Since the α-wave enhancement effect can be obtained with the theanine content, it greatly contributes to the food and pharmaceutical industries.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004041255A JP5005879B2 (en) | 2004-02-18 | 2004-02-18 | Anti-stress and relaxing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004041255A JP5005879B2 (en) | 2004-02-18 | 2004-02-18 | Anti-stress and relaxing composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005232045A JP2005232045A (en) | 2005-09-02 |
JP5005879B2 true JP5005879B2 (en) | 2012-08-22 |
Family
ID=35015366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004041255A Expired - Lifetime JP5005879B2 (en) | 2004-02-18 | 2004-02-18 | Anti-stress and relaxing composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5005879B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023113278A1 (en) * | 2021-12-15 | 2023-06-22 | 아주대학교산학협력단 | Anti-stress composition comprising natural extract mixture, and use thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100870381B1 (en) * | 2004-10-14 | 2008-11-25 | 다이킨 고교 가부시키가이샤 | Method for modifying the ambience, and spray liquid and sprayer used in the method |
JP2006290802A (en) * | 2005-04-11 | 2006-10-26 | Kanebo Cosmetics Inc | New diagnostic method for constitution and counseling method using the diagnosis |
DK2060192T3 (en) * | 2007-10-17 | 2016-02-22 | Wild Gmbh & Co Kg Rudolf | Composition comprising lemon balm extracts |
US20090175964A1 (en) * | 2007-12-14 | 2009-07-09 | Conopco, Inc. D/B/A Unilever | Composition for enhancing immunity |
JP2009221139A (en) * | 2008-03-14 | 2009-10-01 | Morinaga & Co Ltd | Stress inhibitor |
JP2014217287A (en) * | 2013-05-02 | 2014-11-20 | 株式会社エモテント | Anti-stress composition |
MY174991A (en) * | 2014-09-04 | 2020-06-01 | Biotropics Malaysia Berhad | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system |
DE102015009525A1 (en) | 2015-07-17 | 2017-01-19 | Ulrich Jüstrich Holding AG | Novel compositions for use in premenopausal and menopausal women to provide improved nutritional supplementation and / or relief of menopausal symptoms |
JP6686728B2 (en) * | 2016-06-22 | 2020-04-22 | ユーハ味覚糖株式会社 | Functional hard candy and method for producing the same |
JP7037161B2 (en) * | 2016-07-07 | 2022-03-16 | 株式会社東洋新薬 | Oral composition |
JP7164973B2 (en) * | 2018-06-12 | 2022-11-02 | エスエス製薬株式会社 | tablet composition |
JP7095925B1 (en) * | 2021-07-13 | 2022-07-05 | 株式会社東洋新薬 | Oral composition for stress reduction |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06699B2 (en) * | 1984-08-11 | 1994-01-05 | カネボウ食品株式会社 | Mental stability chewing gum |
JP3875733B2 (en) * | 1994-12-16 | 2007-01-31 | 株式会社 伊藤園 | Body acetaldehyde metabolism promoter and method for producing the same |
JP3654710B2 (en) * | 1996-05-28 | 2005-06-02 | 太陽化学株式会社 | Flavor improving composition |
JPH11215973A (en) * | 1998-01-30 | 1999-08-10 | House Foods Corp | Beverage containing fruit and herb |
JP4402756B2 (en) * | 1998-08-06 | 2010-01-20 | 太陽化学株式会社 | Obesity suppressing composition |
JP4653269B2 (en) * | 1999-02-23 | 2011-03-16 | 太陽化学株式会社 | Theanine-containing composition |
JP4824152B2 (en) * | 2000-04-28 | 2011-11-30 | 太陽化学株式会社 | Blood flow improver |
JP3519377B2 (en) * | 2001-04-06 | 2004-04-12 | 株式会社ヤクルト本社 | Herbal beverages |
JP4812968B2 (en) * | 2001-06-06 | 2011-11-09 | 太陽化学株式会社 | Composition for improving attention deficit / hyperactivity disorder |
JP2003164259A (en) * | 2001-11-30 | 2003-06-10 | Otsuka Yakuhin Kogyo Kk | Antioxidant tea |
JP2003183174A (en) * | 2001-12-19 | 2003-07-03 | Fancl Corp | Composition for insomnia |
JP2003252755A (en) * | 2002-03-04 | 2003-09-10 | Pharmafoods Kenkyusho:Kk | Healing-effect composition |
JP2003252756A (en) * | 2002-03-04 | 2003-09-10 | Pharmafoods Kenkyusho:Kk | Dopamine isolation inhibiting composition |
JP4462838B2 (en) * | 2002-04-19 | 2010-05-12 | 三井製糖株式会社 | Alpha wave release enhancer, agent that can lead to a relaxed state, and food and drink containing the agent |
JP2003321355A (en) * | 2002-04-25 | 2003-11-11 | Otsuka Chemical Holdings Co Ltd | Stress restraining composition, granulation containing teanin and manufacturing method thereof |
-
2004
- 2004-02-18 JP JP2004041255A patent/JP5005879B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023113278A1 (en) * | 2021-12-15 | 2023-06-22 | 아주대학교산학협력단 | Anti-stress composition comprising natural extract mixture, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2005232045A (en) | 2005-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4961087B2 (en) | Sleep promoting composition | |
EP1057483B1 (en) | Composition comprising theanine | |
US10398741B2 (en) | Composition | |
JP5005879B2 (en) | Anti-stress and relaxing composition | |
JP2013509395A (en) | Preparations containing amino acids and plants and their activity in alcohol detoxification | |
JP5300167B2 (en) | Composition for treating mood disorders | |
JP2013241354A (en) | Phosphodiesterase 2 inhibitor | |
JP2006265177A (en) | Composition for improving tic disorder | |
KR20190030642A (en) | Composition for enhancing brain activity | |
JP5594819B2 (en) | Composition for improving lipid metabolism | |
JP2014237715A (en) | Agent for alleviating alcoholic fatigue | |
JP4824152B2 (en) | Blood flow improver | |
JP2002363074A (en) | Composition for improving attention-deficit hyperactivity disorder | |
JP4971535B2 (en) | Premenstrual syndrome inhibiting composition | |
JP5122709B2 (en) | Composition for improving mental concentration | |
JP2020080803A (en) | Spice, bonito extract and kelp extract-containing composition | |
KR20090045721A (en) | Compositions for improving sleep disturbance | |
CA2459240C (en) | Pharmaceutical composition for treating mood disorders | |
JP2005206462A (en) | Composition for mitigating or eliminating anxiety disorder | |
JP4883853B2 (en) | Dysmenorrhea composition | |
JP5913395B2 (en) | Beverage | |
JP6234838B2 (en) | Beverage | |
JP2019107039A (en) | Concentration enhancer | |
JP2006306792A (en) | Hepatic function-protecting or improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100830 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111031 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120427 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120524 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150601 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5005879 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |